Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C

T.J. Price, D. Zannino, K. Wilson, R.J. Simes, J. Cassidy, Guy Van Hazel, B.A. Robinson, A. Broad, V. Ganju, S.P. Ackland, N.C. Tebbutt

    Research output: Contribution to journalArticlepeer-review

    111 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)1531-1536
    JournalAnnals of Oncology
    Publication statusPublished - 2012

    Cite this